Today: 20 May 2026
UnitedHealth (UNH) stock rebounds after rout — what investors watch next on Medicare Advantage rates
28 January 2026
1 min read

UnitedHealth (UNH) stock rebounds after rout — what investors watch next on Medicare Advantage rates

NEW YORK, Jan 28, 2026, 11:15 EST — Regular session

  • UnitedHealth shares climbed roughly 3% Wednesday, following a steep drop of nearly 20% the day before.
  • Investors are reevaluating earnings potential after a softer 2026 revenue forecast and a nearly flat Medicare Advantage payment update for 2027.
  • Coming up next is the government’s final Medicare Advantage rate announcement, set for early April.

Shares of UnitedHealth Group Incorporated climbed roughly 3% to $291.23 in Wednesday morning trading, recovering from an intraday low close to $282 following a steep drop on Tuesday.

The rebound fails to wipe away the fresh baseline investors received just a day earlier. On Tuesday, UnitedHealth projected 2026 revenue exceeding $439.0 billion, following 2025 revenue of $447.6 billion. CEO Stephen Hemsley noted the company closed 2025 “as a much stronger company.” unitedhealthgroup.com

Washington acted quickly. The U.S. proposed a modest 0.09% hike in 2027 payments to private insurers handling Medicare Advantage plans. CMS Administrator Mehmet Oz framed the move as an effort to make Medicare Advantage “work better for the people it serves.” Kevin Gade, COO at Bahl & Gaynor, which owns UnitedHealth shares, noted the market had been expecting a bump closer to 4 to 5%. Reuters

The rate shock triggered a sharp sell-off in managed-care stocks Tuesday. Baird’s Michael Ha warned the move could lead to “benefit reductions or plan exits.” Bernstein’s Lance Wilkes flagged that “membership growth will remain low” if the figures hold, while Leerink’s Whit Mayo dismissed the proposal as “well below expectations.” Reuters

UnitedHealth added pressure with its latest forecast. The company expects revenue to drop for the first time since 1989, projecting adjusted profit over $17.75 per share in 2026. It also set the 2026 medical care ratio—premiums allocated to medical claims—at roughly 88.8%. CEO Tim Noel warned that plans may require “very meaningful benefit reductions.” Investor James Harlow of Novare Capital flagged the Medicare proposal as a risk to 2027 earnings growth, while Morningstar’s Julie Utterback noted that “a quick turnaround may have to wait longer.” Reuters

This is now a calendar trade. CMS will release the final Medicare Advantage capitation rates and payment rules for 2027 by April 6, with comments on the advance notice due by Feb. 25.

Peers continue to influence trading. On Wednesday, Elevance Health projected 2026 profits below expectations, warning that high medical costs will continue to pressure insurers. CEO Gail Boudreaux described 2026 as a “year of execution and repositioning.” Reuters

That rebound in UNH might not last. Should final Medicare Advantage rates hold close to the proposal and medical expenses climb beyond what insurers budgeted, the sector could respond by cutting benefits, narrowing networks, or retreating from certain markets — strategies that safeguard margins but threaten membership and expansion.

Traders are focused on two key points: whether the government eases its rate proposal and how UnitedHealth adjusts plan offerings and pricing following a year marked by higher utilization and restructuring costs.

Stock Market Today

  • ASX Penny Stocks: Audinate Group, Alcidion Group, and Austin Engineering Highlighted
    May 19, 2026, 10:46 PM EDT. The Australian stock market faces uncertainty due to high U.S. bond yields and inflation concerns. Investors eye penny stocks-smaller companies with growth potential at lower prices. Audinate Group (A$191.43M market cap) is unprofitable but debt-free, showing strong assets over liabilities and a 14.5% expected revenue growth. Alcidion Group (A$147.72M) is debt-free, profitable with recent net income of A$1.33 million, and forecasted earnings growth of 28%, boosted by a strategic acquisition in healthcare software. Austin Engineering (A$115.28M) specializes in mining equipment manufacturing. These companies highlight different paths to stability and growth amid broader market volatility.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Commvault stock steadies premarket after 31% wipeout on ARR worries
Previous Story

Commvault stock steadies premarket after 31% wipeout on ARR worries

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal
Next Story

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Go toTop